Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02578901 · ClinicalTrials.gov registry record · Phase 3
American Trial Using Tranexamic Acid in Thrombocytopenia
A Phase 3 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
NCT02578901 is a Phase 3 study that has completed, run by University of Washington. The registered enrollment target is 330 participants.
The verdict
NCT02578901, a Phase 3 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the usefulness of antifibrinolytic therapy with tranexamic acid (TXA) in preventing bleeding in patients who are thrombocytopenic due to primary bone marrow disorders or chemotherapy, immunotherapy and/or radiation therapy.
Interventions
- DRUG Placebo
- DRUG Tranexamic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2016-06 |
| Est. Completion | 2020-06-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02578901
The ClinicalTrials.gov registry entry for NCT02578901 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02578901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02578901 about?
NCT02578901 is a clinical study titled "American Trial Using Tranexamic Acid in Thrombocytopenia". The purpose of this study is to evaluate the usefulness of antifibrinolytic therapy with tranexamic acid (TXA) in preventing bleeding in patients who are thrombocytopenic due to primary bone marrow disorders or chemotherapy, immunotherapy and/or radiation therapy.
What is the current status of trial NCT02578901?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2016-06. Estimated completion is 2020-06-11.
What interventions are being tested in trial NCT02578901?
The interventions under investigation include: Placebo (DRUG), Tranexamic Acid (DRUG).
Who is sponsoring clinical trial NCT02578901?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.